Cargando…

Aripiprazole LAI two‐injection start in a 16 year‐old adolescent with schizophrenia

BACKGROUND: Aripiprazole long‐acting injection (LAI) is approved for the treatment of schizophrenia in adults. Recently, Europe and Canada approved the use of the two‐injection start regimen: two separate injections of 400‐mg long‐acting aripiprazole along with a single 20‐mg dose of oral aripiprazo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salvi, Virginio, Appignanesi, Cristina, Marpepa, Brodinela, Orsolini, Laura, Volpe, Umberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216357/ https://www.ncbi.nlm.nih.gov/pubmed/35182040 http://dx.doi.org/10.1002/npr2.12240

Ejemplares similares

Aripiprazole lai two-injection start in a 16 year-old with Schizophrenia
por: Marpepa, B., et al.
Publicado: (2022)

Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
por: Lauriello, John, et al.
Publicado: (2021)

A Systematic Review on TeleMental Health in Youth Mental Health: Focus on Anxiety, Depression and Obsessive-Compulsive Disorder
por: Orsolini, Laura, et al.
Publicado: (2021)

Long-acting paliperidone in Ekbom’s syndrome in Lewy body dementia: A case report
por: Orsolini, Laura, et al.
Publicado: (2022)

Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
por: Romero Guillena, S.L., et al.
Publicado: (2022)

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
por: Potkin, Steven, et al.
Publicado: (2013)

An observational naturalistic study on non-suicidal self-harm behaviours in a cohort of adolescents and young inpatients during COVID-19 outbreak
por: Orsolini, L., et al.
Publicado: (2022)

Effects of aripiprazole long-acting two-injection start in patients diagnosed with schizophrenia in Huelva (Spain)
por: Moleon, A., et al.
Publicado: (2023)

The place of Long Acting Injectables (LAI) in the treatment of Schizophrenia: Current perspectives
Publicado: (2022)

ADHD and Bipolar Disorder in Adulthood: Clinical and Treatment Implications
por: Salvi, Virginio, et al.
Publicado: (2021)

Fear and anxiety related to COVID-19 pandemic may predispose to perinatal depression in Italy
por: Orsolini, Laura, et al.
Publicado: (2022)

C-Reactive Protein as a Biomarker for Major Depressive Disorder?
por: Orsolini, Laura, et al.
Publicado: (2022)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo, Ilaria, et al.
Publicado: (2018)

The Effect of Switching to Long-Acting Injection (LAI) Antipsychotic Therapy on Patients with Schizophrenia
por: STRUNOIU, LIVIA MIHAELA, et al.
Publicado: (2021)

Differences in autonomic nervous system activity between long-acting injectable aripiprazole and oral aripiprazole in schizophrenia
por: Hattori, Saki, et al.
Publicado: (2023)

A study on blood pressure changes following Olanzapine Long Acting Injection (LAI) in schizophrenia
por: Gakkhar, Shivam, et al.
Publicado: (2022)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
por: James, Suneeta, et al.
Publicado: (2016)

Lais /
por: France, Marie de
Publicado: (1994)

Challenges in Treating Schizophrenia with LAIs – Analysis of Own Results
por: Todorov, A. A., et al.
Publicado: (2023)

Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia
por: Kamei, Hiroyuki, et al.
Publicado: (2020)

A Preliminary Italian Cross-Sectional Study on the Level of Digital Psychiatry Training, Knowledge, Beliefs and Experiences among Medical Students, Psychiatry Trainees and Professionals
por: Orsolini, Laura, et al.
Publicado: (2022)

T231. PALIPERIDONE LONG-ACTING INJECTABLE (LAI) IS ASSOCIATED WITH A LOWER INTAKE OF BENZODIAZEPINES AND A LOWER NUMBER OF ADMISSIONS COMPARED WITH OTHER LAIS IN A COHORT OF PATIENTS WITH SCHIZOPHRENIA
por: Garcia-Carmona, Juan-Antonio
Publicado: (2018)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Corrigendum to “Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia”
por: James, Suneeta, et al.
Publicado: (2019)

Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010)

Review of depot aripiprazole for schizophrenia
por: Motiwala, Farha Bilal, et al.
Publicado: (2013)

Depressive and Anxious Temperaments as Predictors of Late Onset Bipolar Disorder? Preliminary Results of a “Real World” Exploratory Study
por: Orsolini, Laura, et al.
Publicado: (2022)

Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2017)

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
por: Giordano, Gloria, et al.
Publicado: (2020)

Schizophrenia: A Narrative Review of Etiopathogenetic, Diagnostic and Treatment Aspects
por: Orsolini, Laura, et al.
Publicado: (2022)

Clozapine-Treatment-Resistant Schizophrenia Successfully Managed with Brexpiprazole Combination Therapy: Two Case Reports
por: Orsolini, L., et al.
Publicado: (2022)

When to start aripiprazole therapy in patients with bipolar mania
por: Sayyaparaju, Kiran Kumar, et al.
Publicado: (2014)

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb, Nilufar, et al.
Publicado: (2012)

S206. ARIPIPRAZOLE LONG-ACTING INJECTABLE IN SCHIZOPHRENIA DURING PREGNANCY: A CASE REPORT
por: Sole, Eva, et al.
Publicado: (2020)

Long-acting injectable aripiprazole in pregnant women with schizophrenia: a case-series report
por: Fernández-Abascal, Blanca, et al.
Publicado: (2021)

Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia
por: Kim, Sung-Wan, et al.
Publicado: (2023)

Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia
por: Hard, Marjie L., et al.
Publicado: (2018)

Drug attitude inventory is relevant to LAI treatment persistence in schizophrenia: Preliminary results
por: D’Anna, G., et al.
Publicado: (2021)

Schizophrenia treatment with a combination of two LAI antipsychotics: A case report
por: Jarosz, Marcin, et al.
Publicado: (2022)

Estimating Leaf Area Index (LAI) in Vineyards Using the PocketLAI Smart-App
por: Orlando, Francesca, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bp4i8prc8d5nqc2r337nljg6nm